Showing 4291-4300 of 7011 results for "".
- Contrast Media in Hospitalized Patients with AKI: Renal and Clinical Outcomeshttps://reachmd.com/news/contrast-media-in-hospitalized-patients-with-aki-renal-and-clinical-outcomes/2485925/Hospital teams often weigh diagnostic yield against renal risk when considering iodinated contrast in patients with acute kidney injury (AKI). In
- Cyberbullying and Adolescent Mental Health: Clinician Update from a Systematic Reviewhttps://reachmd.com/news/cyberbullying-and-adolescent-mental-health-clinician-update-from-a-systematic-review/2485933/Casaña Mohedo and colleagues report a PRISMA 2020 systematic review synthesizing 42 studies of adolescents aged 10–19 years on cyberbullying victimizatio
- Low‑dose Lithium and Verbal Memory in MCIhttps://reachmd.com/news/low-dose-lithium-mci/2485882/In a JAMA Neurology study, low-dose oral lithium was compared with placebo over two years in older adults with mild cognitive impairment (MCI), with an explora
- Dual 1550/1927-nm Laser System Shows Favorable Outcomes in Skin of Colorhttps://reachmd.com/news/dual-15501927-nm-laser-system-shows-favorable-outcomes-in-skin-of-color/2485840/Non-ablative fractional laser treatments are widely used for dyschromia, scarring, and photoaging, yet data in patients with skin of color remain comparatively limited. In a review published online in Lasers in Surgery and Medicine, the authors evaluated the safety and efficacy of a dual
- EMA Panel Backs Baricitinib for Adolescents With Severe Alopecia Areatahttps://reachmd.com/news/ema-panel-backs-baricitinib-for-adolescents-with-severe-alopecia-areata/2485850/The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of baricitinib (Olumiant, Eli Lilly and Company), a once-daily oral Janus kinase (JAK) inhibitor, for adolescents aged 12 to yo
- Sex Differences in Coronary Plaque Burden and Event Risk (PROMISE Subset)https://reachmd.com/news/sex-differences-in-coronary-plaque-burden-and-event-risk-promise-subset/2485821/In a PROMISE trial subset, investigators reported that women undergoing coronary CT angiography had less overall coronary plaque than men, yet their subsequent clinical eve
- Most Nations Off Track to Meet 2030 Skin NTD SDG Targets: Reporthttps://reachmd.com/news/most-nations-off-track-to-meet-2030-skin-ntd-sdg-targets-report/2485823/A new report in JAMA Dermatology revealed that most countries are unlikely to achieve the World Health Organization (WHO) target of a 75% reduction in disability-adjusted life-years (DALYs) from skin-related neglected tropical diseases (NTDs) from 2020 lev
- Projected Impacts of Integrated T2D Management in Spainhttps://reachmd.com/news/impacts-of-integrated-t2d-management-spain/2485774/An MDPI Journal of Clinical Medicine modeling analysis estimated the one-year national impact in Spain of simultaneously meeting three biomarke
- ETVAX Trial in the Gambia: Reported Protection Against Severe Childhood Diarrheahttps://reachmd.com/news/etvax-trial-in-the-gambia-reported-protection-against-severe-childhood-diarrhea/2485728/Reported results suggest that the oral enterotoxigenic Escherichia coli (ETEC) vaccine candidate ETVAX showed efficacy signals against moderate-to-severe ETEC-associated diarrheal illness in young children
- Analysis Forecasts 140% Rise in Basal Cell Carcinoma Incidence by 2050https://reachmd.com/news/analysis-forecasts-140-rise-in-basal-cell-carcinoma-incidence-by-2050/2485719/An analysis projected that incident basal cell carcinoma (BCC) among adults aged 65 ye